Menu Search
Equities

Summit Therapeutics Inc

SMMT:NMQ

Summit Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.90
  • Today's Change0.48 / 2.61%
  • Shares traded209.51k
  • 1 Year change+869.23%
  • Beta-0.9162
Data delayed at least 15 minutes, as of Nov 22 2024 15:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Summit Therapeutics Inc's revenues fell -100.00% from 705.00k to 0.00. has fallen 680.54% from a loss of 78.78m to a larger loss of 614.93m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-54.53%
Return on equity-73.21%
Return on investment-71.71%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Summit Therapeutics Inc fell by 577.18m. Cash Flow from Financing totalled 86.51m or -- of revenues. In addition the company used 76.76m for operations while cash used for investing totalled 587.77m.
Cash flow per share-0.2771
Price/Cash flow per share--
Book value per share0.5941
Tangible book value per share0.5914
More ▼

Balance sheet in USDView more

Summit Therapeutics Inc has a Debt to Total Capital ratio of 5.30%.
Current ratio8.31
Quick ratio--
Total debt/total equity0.056
Total debt/total capital0.053
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.